SNP 318
Alternative Names: SNP-318Latest Information Update: 04 Dec 2023
At a glance
- Originator GlaxoSmithKline
- Developer SciNeuro Pharmaceuticals
- Class Antidementias; Small molecules
- Mechanism of Action 1-alkyl-2-acetylglycerophosphocholine esterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dementia
Most Recent Events
- 30 Nov 2023 Adverse events, pharmacodynamics and pharmacokinetics data from a phase I trial in Dementia released by SciNeuro Pharmaceuticals
- 30 Nov 2023 SciNeuro Pharmaceuticals plans a phase II trial for Alzheimer's disease (PO) in 2024
- 29 Nov 2023 SciNeuro Pharmaceuticals completes phase I trial in Dementia (In volunteers) in Australia (PO) (NCT05792163)